Molecular dissection of complete response to receptor tyrosine kinase inhibition in type II papillary renal cell carcinoma

Matti Annala, Lucia Nappi, Arun A Azad, Fan Mo, Ladan Fazli, Kim N Chi, Alexander W Wyatt

Research output: Contribution to journalArticleOtherpeer-review

Abstract

Metastatic papillary renal cell carcinoma (pRCC) is invariably lethal. Receptor tyrosine kinase inhibitors such as sunitinib malate are demonstrated to prolong survival but resistance is inevitable and clinical responses greater than one year are very rare. Hereditary leiomyomatosis and renal cell cancer (HLRCC) is a rare inherited disorder caused by germline mutation to the fumarate hydratase (FH) gene and characterized in part by FH-deficient pRCC tumors that are particularly aggressive. We present a remarkable case of FH-deficient metastatic pRCC who has experienced an 8 year complete response to receptor tyrosine kinase inhibitors sunitinib malate and pazopanib. We performed exome sequencing on her primary and metastatic tumors and reveal relevant genomic alterations including amplification of the growth factor effector GRB2, and mutations to critical DNA damage repair genes that are not normally perturbed in pRCC or indeed renal cell carcinoma (RCC) in general. We posit that defects to these genes and pathways could influence the response of RCC to RTK inhibitors, and that other RCC patients with strong response to therapy should be evaluated for similar genomic aberrations.
Original languageEnglish
Pages (from-to)e145-e150
Number of pages6
JournalClinical Genitourinary Cancer
Volume15
Issue number1
DOIs
Publication statusPublished - Feb 2017

Keywords

  • DNA damage repair
  • fumarate hydratase
  • hereditary leiomyomatosis and renal cell cancer
  • Pazopanib
  • Sunitinib

Cite this

Annala, Matti ; Nappi, Lucia ; Azad, Arun A ; Mo, Fan ; Fazli, Ladan ; Chi, Kim N ; Wyatt, Alexander W. / Molecular dissection of complete response to receptor tyrosine kinase inhibition in type II papillary renal cell carcinoma. In: Clinical Genitourinary Cancer. 2017 ; Vol. 15, No. 1. pp. e145-e150.
@article{7e76aa500dd6480db6e5b0c1c3192539,
title = "Molecular dissection of complete response to receptor tyrosine kinase inhibition in type II papillary renal cell carcinoma",
abstract = "Metastatic papillary renal cell carcinoma (pRCC) is invariably lethal. Receptor tyrosine kinase inhibitors such as sunitinib malate are demonstrated to prolong survival but resistance is inevitable and clinical responses greater than one year are very rare. Hereditary leiomyomatosis and renal cell cancer (HLRCC) is a rare inherited disorder caused by germline mutation to the fumarate hydratase (FH) gene and characterized in part by FH-deficient pRCC tumors that are particularly aggressive. We present a remarkable case of FH-deficient metastatic pRCC who has experienced an 8 year complete response to receptor tyrosine kinase inhibitors sunitinib malate and pazopanib. We performed exome sequencing on her primary and metastatic tumors and reveal relevant genomic alterations including amplification of the growth factor effector GRB2, and mutations to critical DNA damage repair genes that are not normally perturbed in pRCC or indeed renal cell carcinoma (RCC) in general. We posit that defects to these genes and pathways could influence the response of RCC to RTK inhibitors, and that other RCC patients with strong response to therapy should be evaluated for similar genomic aberrations.",
keywords = "DNA damage repair, fumarate hydratase, hereditary leiomyomatosis and renal cell cancer, Pazopanib, Sunitinib",
author = "Matti Annala and Lucia Nappi and Azad, {Arun A} and Fan Mo and Ladan Fazli and Chi, {Kim N} and Wyatt, {Alexander W}",
year = "2017",
month = "2",
doi = "10.1016/j.clgc.2016.05.019",
language = "English",
volume = "15",
pages = "e145--e150",
journal = "Clinical Genitourinary Cancer",
issn = "1558-7673",
publisher = "Elsevier",
number = "1",

}

Molecular dissection of complete response to receptor tyrosine kinase inhibition in type II papillary renal cell carcinoma. / Annala, Matti; Nappi, Lucia; Azad, Arun A; Mo, Fan; Fazli, Ladan; Chi, Kim N; Wyatt, Alexander W.

In: Clinical Genitourinary Cancer, Vol. 15, No. 1, 02.2017, p. e145-e150.

Research output: Contribution to journalArticleOtherpeer-review

TY - JOUR

T1 - Molecular dissection of complete response to receptor tyrosine kinase inhibition in type II papillary renal cell carcinoma

AU - Annala, Matti

AU - Nappi, Lucia

AU - Azad, Arun A

AU - Mo, Fan

AU - Fazli, Ladan

AU - Chi, Kim N

AU - Wyatt, Alexander W

PY - 2017/2

Y1 - 2017/2

N2 - Metastatic papillary renal cell carcinoma (pRCC) is invariably lethal. Receptor tyrosine kinase inhibitors such as sunitinib malate are demonstrated to prolong survival but resistance is inevitable and clinical responses greater than one year are very rare. Hereditary leiomyomatosis and renal cell cancer (HLRCC) is a rare inherited disorder caused by germline mutation to the fumarate hydratase (FH) gene and characterized in part by FH-deficient pRCC tumors that are particularly aggressive. We present a remarkable case of FH-deficient metastatic pRCC who has experienced an 8 year complete response to receptor tyrosine kinase inhibitors sunitinib malate and pazopanib. We performed exome sequencing on her primary and metastatic tumors and reveal relevant genomic alterations including amplification of the growth factor effector GRB2, and mutations to critical DNA damage repair genes that are not normally perturbed in pRCC or indeed renal cell carcinoma (RCC) in general. We posit that defects to these genes and pathways could influence the response of RCC to RTK inhibitors, and that other RCC patients with strong response to therapy should be evaluated for similar genomic aberrations.

AB - Metastatic papillary renal cell carcinoma (pRCC) is invariably lethal. Receptor tyrosine kinase inhibitors such as sunitinib malate are demonstrated to prolong survival but resistance is inevitable and clinical responses greater than one year are very rare. Hereditary leiomyomatosis and renal cell cancer (HLRCC) is a rare inherited disorder caused by germline mutation to the fumarate hydratase (FH) gene and characterized in part by FH-deficient pRCC tumors that are particularly aggressive. We present a remarkable case of FH-deficient metastatic pRCC who has experienced an 8 year complete response to receptor tyrosine kinase inhibitors sunitinib malate and pazopanib. We performed exome sequencing on her primary and metastatic tumors and reveal relevant genomic alterations including amplification of the growth factor effector GRB2, and mutations to critical DNA damage repair genes that are not normally perturbed in pRCC or indeed renal cell carcinoma (RCC) in general. We posit that defects to these genes and pathways could influence the response of RCC to RTK inhibitors, and that other RCC patients with strong response to therapy should be evaluated for similar genomic aberrations.

KW - DNA damage repair

KW - fumarate hydratase

KW - hereditary leiomyomatosis and renal cell cancer

KW - Pazopanib

KW - Sunitinib

UR - https://www-scopus-com.ezproxy.lib.monash.edu.au/record/display.uri?eid=2-s2.0-85008402264&origin=resultslist&

U2 - 10.1016/j.clgc.2016.05.019

DO - 10.1016/j.clgc.2016.05.019

M3 - Article

VL - 15

SP - e145-e150

JO - Clinical Genitourinary Cancer

JF - Clinical Genitourinary Cancer

SN - 1558-7673

IS - 1

ER -